Skip to main content
Erschienen in: Journal of Clinical Immunology 1/2020

08.11.2019 | Original Article

STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib

verfasst von: Xiaolei Tang, Hui Xu, Chunju Zhou, Yun Peng, Hui Liu, Jinrong Liu, Huimin Li, Haiming Yang, Shunying Zhao

Erschienen in: Journal of Clinical Immunology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

STING-associated vasculopathy with onset in infancy (SAVI) is a new rare auto-inflammatory disease. The purpose of this study is to report new cases and summarize the manifestations and outcome of SAVI.

Methods

We made a retrospective analysis of three pediatric patients diagnosed with SAVI between March 2016 and July 2018 in Beijing Children’s Hospital.

Results

Three patients comprised one boy and two girls. The median age of onset was 4 months. All patients had the same de novo heterozygous mutation (c.463G>A, p. V155M) of TMEM173. All patients presented with interstitial lung disease and one coexisted with diffuse alveolar hemorrhage. Rashes were presented in two patients. Other clinical manifestations include febrile attacks, failure to thrive, arthritis, myositis, cerebrovascular involvement, ureteral calculus, gastroesophageal reflux, and malnutrition. Ground-glass opacities were the most common features of chest computed tomography, followed with cysts and reticular opacities. Transbronchial lung biopsy was performed in one patient revealing pulmonary vasculitis. Skin biopsy was performed in one patient with changes of vasculitis. All patients were treated with corticosteroids and two patients received combined treatment of tofacitinib. The therapeutic effects of tofacitinib were limited on interstitial lung disease in both patients and were poor on rashes in one patient. One patient under the treatment of tofacitinib died.

Conclusions

New clinical aspect of diffuse alveolar hemorrhage is first reported to be associated with SAVI. Unsatisfactory therapeutic effects of tofacitinib are observed in this study and further evaluations are needed.
Literatur
1.
Zurück zum Zitat Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–18.CrossRef Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–18.CrossRef
2.
Zurück zum Zitat Picard C, Mathieu A-L, Hasan U, Henry T, Jamilloux Y, Walzer T, et al. Inherited anomalies of innate immune receptors in pediatric-onset inflammatory diseases. Autoimmun Rev. 2015;14(12):1147–53.CrossRef Picard C, Mathieu A-L, Hasan U, Henry T, Jamilloux Y, Walzer T, et al. Inherited anomalies of innate immune receptors in pediatric-onset inflammatory diseases. Autoimmun Rev. 2015;14(12):1147–53.CrossRef
3.
Zurück zum Zitat Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516–20.CrossRef Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516–20.CrossRef
4.
Zurück zum Zitat Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Rieux-Laucat F, et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest. 2016;150(3):e65–71.CrossRef Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Rieux-Laucat F, et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest. 2016;150(3):e65–71.CrossRef
5.
Zurück zum Zitat Yu Z, Zhong L, Song H, et al. Stimulator of interferon genes-associated vasculopathy with onset in infancy: first case report in China. Chin J Pediatr. 2018;56(3):179–85. Yu Z, Zhong L, Song H, et al. Stimulator of interferon genes-associated vasculopathy with onset in infancy: first case report in China. Chin J Pediatr. 2018;56(3):179–85.
6.
Zurück zum Zitat Shoman W, El Chazli Y, ElSawy I, et al. First Egyptian patient with STING-associated vasculopathy with onset in infancy. Scand J Rheumatol. 2019;22:1–2. Shoman W, El Chazli Y, ElSawy I, et al. First Egyptian patient with STING-associated vasculopathy with onset in infancy. Scand J Rheumatol. 2019;22:1–2.
7.
Zurück zum Zitat Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, et al. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheum. 2015;67(3):808.CrossRef Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, et al. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheum. 2015;67(3):808.CrossRef
8.
Zurück zum Zitat Melki I, Rose Y, Uggenti C, van Eyck L, Frémond ML, Kitabayashi N, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol. 2017;140(2):543–52.CrossRef Melki I, Rose Y, Uggenti C, van Eyck L, Frémond ML, Kitabayashi N, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol. 2017;140(2):543–52.CrossRef
9.
Zurück zum Zitat Munoz J, Rodière M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, et al. Stimulator of interferon genes–associated vasculopathy with onset in infancy a mimic of childhood granulomatosis with polyangiitis. JAMA Dermatol. 2015;151(8):872–7.CrossRef Munoz J, Rodière M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, et al. Stimulator of interferon genes–associated vasculopathy with onset in infancy a mimic of childhood granulomatosis with polyangiitis. JAMA Dermatol. 2015;151(8):872–7.CrossRef
10.
Zurück zum Zitat Chia J, Eroglu FK, Özen S, Orhan D, Montealegre-Sanchez G, de Jesus AA, et al. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2016 Jan;74(1):186–9.CrossRef Chia J, Eroglu FK, Özen S, Orhan D, Montealegre-Sanchez G, de Jesus AA, et al. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2016 Jan;74(1):186–9.CrossRef
11.
Zurück zum Zitat Sanchez GAM, Reinhardt A, Ramsey S. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–52.CrossRef Sanchez GAM, Reinhardt A, Ramsey S. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–52.CrossRef
12.
Zurück zum Zitat Clarke SL, Pellowe EJ, de Jesus AA, et al. Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy. Am J Respir Crit Care Med. 2016 Sep 1;194(5):639–42.CrossRef Clarke SL, Pellowe EJ, de Jesus AA, et al. Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy. Am J Respir Crit Care Med. 2016 Sep 1;194(5):639–42.CrossRef
13.
Zurück zum Zitat Seo J, Kang JA, Suh DI, Park EB, Lee CR, Choi SA, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396–9.CrossRef Seo J, Kang JA, Suh DI, Park EB, Lee CR, Choi SA, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396–9.CrossRef
14.
Zurück zum Zitat König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017 Feb;76(2):468–72.CrossRef König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017 Feb;76(2):468–72.CrossRef
15.
Zurück zum Zitat Manoussakis MN, Mavragani CP, Nezos A, Zampeli E, Germenis A, Moutsopoulos HM. Type I interferonopathy in a young adult. Rheumatology (Oxford). 2017;56(12):2241–3.CrossRef Manoussakis MN, Mavragani CP, Nezos A, Zampeli E, Germenis A, Moutsopoulos HM. Type I interferonopathy in a young adult. Rheumatology (Oxford). 2017;56(12):2241–3.CrossRef
16.
Zurück zum Zitat Konno H, Chinn IK, Hong D, Orange JS, Lupski JR, Mendoza A, et al. Pro-inflammation associated with a gain-of-function mutation (R284S) in the innate immune sensor STING. Cell Rep. 2018;23(4):1112–23.CrossRef Konno H, Chinn IK, Hong D, Orange JS, Lupski JR, Mendoza A, et al. Pro-inflammation associated with a gain-of-function mutation (R284S) in the innate immune sensor STING. Cell Rep. 2018;23(4):1112–23.CrossRef
17.
Zurück zum Zitat Saldanha RG, Balka KR, Davidson S, Wainstein BK, Wong M, Macintosh R, et al. A mutation outside the dimerization domain causing atypical STING- associated vasculopathy with onset in infancy. Front Immunol. 2018;9:1535.CrossRef Saldanha RG, Balka KR, Davidson S, Wainstein BK, Wong M, Macintosh R, et al. A mutation outside the dimerization domain causing atypical STING- associated vasculopathy with onset in infancy. Front Immunol. 2018;9:1535.CrossRef
18.
Zurück zum Zitat Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J. 2016;14(1):35.CrossRef Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J. 2016;14(1):35.CrossRef
19.
Zurück zum Zitat Volpi S, Tsui J, Mariani M, Pastorino C, Caorsi R, Sacco O, et al. Type I interferon pathway activation in COPA syndrome. Clin Immunol. 2018;187:33–6.CrossRef Volpi S, Tsui J, Mariani M, Pastorino C, Caorsi R, Sacco O, et al. Type I interferon pathway activation in COPA syndrome. Clin Immunol. 2018;187:33–6.CrossRef
20.
Zurück zum Zitat Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20.CrossRef Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20.CrossRef
21.
Zurück zum Zitat Frémond ML, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016 Dec;138(6):1752–5.CrossRef Frémond ML, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016 Dec;138(6):1752–5.CrossRef
22.
Zurück zum Zitat Rodero MP, Frémond ML, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.CrossRef Rodero MP, Frémond ML, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.CrossRef
23.
Zurück zum Zitat Volpi S, Insalaco A, Caorsi R, Santori E, Messia V, Sacco O, et al. Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome. J Clin Immunol. 2019;39(5):476–85.CrossRef Volpi S, Insalaco A, Caorsi R, Santori E, Messia V, Sacco O, et al. Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome. J Clin Immunol. 2019;39(5):476–85.CrossRef
Metadaten
Titel
STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib
verfasst von
Xiaolei Tang
Hui Xu
Chunju Zhou
Yun Peng
Hui Liu
Jinrong Liu
Huimin Li
Haiming Yang
Shunying Zhao
Publikationsdatum
08.11.2019
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 1/2020
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-019-00690-9

Weitere Artikel der Ausgabe 1/2020

Journal of Clinical Immunology 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.